Review Article

β-内酰胺酶及其抑制剂的研究进展

卷 30, 期 7, 2023

发表于: 14 September, 2022

页: [783 - 808] 页: 26

弟呕挨: 10.2174/0929867329666220620165429

价格: $65

摘要

β-内酰胺类抗生素治疗细菌感染非常有效,但过度使用和误用导致了耐药性。β-内酰胺酶能水解β-内酰胺类抗生素,是细菌产生耐药性的主要原因。细菌进化和临床突变产生这种β -内酰胺酶,可以水解新发现的抗生素。因此,碳青霉烯类被认为是抗菌治疗的最后手段。此外,已经发现了不同的抑制剂来对抗这些进化和突变的β-内酰胺酶耐药性。这些抑制剂与β-内酰胺抗生素联合使用可有效治疗细菌感染。但随着时间的推移,人们观察到细菌会对这种组合产生耐药性。这是一篇广泛的综述,讨论了不同种类的β-内酰胺酶,它们的作用机制,以及关键结构元素的作用,如环和催化相关突变。这种突变和结构修饰扩大了活性谱,使这些β-内酰胺酶对新发现的β-内酰胺抗生素及其抑制剂具有耐药性。详细了解这些突变、催化相关的结构修饰、相关的动力学和作用机制有助于有效地开发新的抑制剂。此外,还详细讨论了针对每一类β-内酰胺酶的可用抑制剂。

关键词: β-内酰胺类抗生素,β-内酰胺酶,突变,环,抑制剂,动力学。

[1]
Bush, K. Past and present perspectives on β-lactamases. Antimicrob. Agents Chemother., 2018, 62(10), 62.
[http://dx.doi.org/10.1128/AAC.01076-18] [PMID: 30061284]
[2]
Drawz, S.M.; Bonomo, R.A. Three decades of β-lactamase inhibitors. Clin. Microbiol. Rev., 2010, 23(1), 160-201.
[http://dx.doi.org/10.1128/CMR.00037-09] [PMID: 20065329]
[3]
Galdadas, I.; Qu, S.; Oliveira, A.S.F.; Olehnovics, E.; Mack, A.R.; Mojica, M.F.; Agarwal, P.K.; Tooke, C.L.; Gervasio, F.L.; Spencer, J.; Bonomo, R.A.; Mulholland, A.J.; Haider, S. Allosteric communication in class A β-lactamases occurs via cooperative coupling of loop dynamics. eLife, 2021, 10, e66567.
[http://dx.doi.org/10.7554/eLife.66567] [PMID: 33755013]
[4]
Interagency Coordination Group on Antimicrobial Resistance. No time to wait: Securing the future from drug-resistant infections: World health organization; , 2019. Available from:https://www.who.int/antimicrobial-resistance/interagency-coordination-group/final-report/en/
[5]
Tooke, C.L.; Hinchliffe, P.; Bragginton, E.C.; Colenso, C.K.; Hirvonen, V.H.A.; Takebayashi, Y.; Spencer, J. β-lactamases and β-lactamase inhibitors in the 21st century. J. Mol. Biol., 2019, 431(18), 3472-3500.
[http://dx.doi.org/10.1016/j.jmb.2019.04.002] [PMID: 30959050]
[6]
Palzkill, T. Metallo-β-lactamase structure and function. Ann. N. Y. Acad. Sci., 2013, 1277, 91-104.
[http://dx.doi.org/10.1111/j.1749-6632.2012.06796.x] [PMID: 23163348]
[7]
Bonomo, R.A. β-lactamases: A focus on current challenges. Cold Spring Harb. Perspect. Med., 2017, 7(1), a025239.
[http://dx.doi.org/10.1101/cshperspect.a025239] [PMID: 27742735]
[8]
Öztürk, H.; Ozkirimli, E.; Özgür, A. Classification of Beta-lactamases and penicillin binding proteins using ligand-centric network models. PLoS One, 2015, 10(2), e0117874.
[http://dx.doi.org/10.1371/journal.pone.0117874] [PMID: 25689853]
[9]
Sawa, T.; Kooguchi, K.; Moriyama, K. Molecular diversity of extended-spectrum β-lactamases and carbapenemases, and antimicrobial resistance. J. Intensive Care, 2020, 8, 13.
[10]
Bush, K.; Jacoby, G.A. Updated functional classification of β-lactamases. Antimicrob. Agents Chemother., 2010, 54(3), 969-976.
[http://dx.doi.org/10.1128/AAC.01009-09] [PMID: 19995920]
[11]
Palzkill, T. Structural and mechanistic basis for extended-spectrum drug-resistance mutations in altering the specificity of TEM, CTX-M, and KPC β-lactamases. Front. Mol. Biosci., 2018, 5, 16.
[http://dx.doi.org/10.3389/fmolb.2018.00016] [PMID: 29527530]
[12]
Bajpai, T.; Pandey, M.; Varma, M.; Bhatambare, G.S. Prevalence of TEM, SHV, and CTX-M Beta-Lactamase genes in the urinary isolates of a tertiary care hospital. Avicenna J. Med., 2017, 7(1), 12-16.
[http://dx.doi.org/10.4103/2231-0770.197508] [PMID: 28182026]
[13]
ur Rahman, S.; Ali, T.; Ali, I.; Khan, N.A.; Han, B.; Gao, J. The growing genetic and functional diversity of extended spectrum beta-lactamases. BioMed Res. Int., 2018, 2018, 1-14.
[14]
Pemberton, O.A.; Noor, R.E.; Kumar, M.V.V.; Sanishvili, R.; Kemp, M.T.; Kearns, F.L.; Woodcock, H.L.; Gelis, I.; Chen, Y. Mechanism of proton transfer in class A β-lactamase catalysis and inhibition by avibactam. Proc. Natl. Acad. Sci. USA, 2020, 117(11), 5818-5825.
[http://dx.doi.org/10.1073/pnas.1922203117] [PMID: 32123084]
[15]
Agarwal, V.; Yadav, T.C.; Tiwari, A.; Varadwaj, P. Detailed investigation of catalytically important residues of class A β-lactamase. J. Biomol. Struct. Dyn., 2022, 1-28.
[http://dx.doi.org/10.1080/07391102.2021.2023645] [PMID: 34986744]
[16]
Pan, X.; He, Y.; Lei, J.; Huang, X.; Zhao, Y. Crystallographic snapshots of class A β-lactamase catalysis reveal structural changes that facilitate β-lactam hydrolysis. J. Biol. Chem., 2017, 292(10), 4022-4033.
[http://dx.doi.org/10.1074/jbc.M116.764340] [PMID: 28100776]
[17]
Kar, D.; Pandey, S.D.; Mallick, S.; Dutta, M.; Ghosh, A.S. Substitution of alanine at position 184 with glutamic acid in Escherichia coli PBP5 Ω-like loop introduces a moderate cephalosporinase activity. Protein J., 2018, 37(2), 122-131.
[http://dx.doi.org/10.1007/s10930-018-9765-y] [PMID: 29549627]
[18]
Lobkovsky, E.; Moews, P.C.; Liu, H.; Zhao, H.; Frere, J.M.; Knox, J.R. Evolution of an enzyme activity: Crystallographic structure at 2-A resolution of cephalosporinase from the ampC gene of Enterobacter cloacae P99 and comparison with a class A penicillinase. Proc. Natl. Acad. Sci. USA, 1993, 90(23), 11257-11261.
[http://dx.doi.org/10.1073/pnas.90.23.11257] [PMID: 8248237]
[19]
Egorov, A.; Rubtsova, M.; Grigorenko, V.; Uporov, I.; Veselovsky, A. The role of the Ω-loop in regulation of the catalytic activity of TEM-type β-lactamases. Biomolecules, 2019, 9(12), 854.
[http://dx.doi.org/10.3390/biom9120854] [PMID: 31835662]
[20]
Chaïbi, E.B.; Sirot, D.; Paul, G.; Labia, R. Inhibitor-resistant TEM β-lactamases: Phenotypic, genetic and biochemical characteristics. J. Antimicrob. Chemother., 1999, 43(4), 447-458.
[http://dx.doi.org/10.1093/jac/43.4.447] [PMID: 10350372]
[21]
Sampson, J.M.; Ke, W.; Bethel, C.R.; Pagadala, S.R.R.; Nottingham, M.D.; Bonomo, R.A.; Buynak, J.D.; van den Akker, F. Ligand-dependent disorder of the Ω loop observed in extended-spectrum SHV-type β-lactamase. Antimicrob. Agents Chemother., 2011, 55(5), 2303-2309.
[http://dx.doi.org/10.1128/AAC.01360-10] [PMID: 21357298]
[22]
Sideraki, V.; Huang, W.; Palzkill, T.; Gilbert, H.F. A secondary drug resistance mutation of TEM-1 beta-lactamase that suppresses misfolding and aggregation. Proc. Natl. Acad. Sci. USA, 2001, 98(1), 283-288.
[http://dx.doi.org/10.1073/pnas.011454198] [PMID: 11114163]
[23]
Dellus-Gur, E.; Elias, M.; Caselli, E.; Prati, F.; Salverda, M.L.M.; de Visser, J.A.G.M.; Fraser, J.S.; Tawfik, D.S. Negative epistasis and evolvability in TEM-1 β-lactamase-the thin line between an enzyme’s conformational freedom and disorder. J. Mol. Biol., 2015, 427(14), 2396-2409.
[http://dx.doi.org/10.1016/j.jmb.2015.05.011] [PMID: 26004540]
[24]
Stojanoski, V.; Chow, D-C.; Hu, L.; Sankaran, B.; Gilbert, H.F.; Prasad, B.V.V.; Palzkill, T. A triple mutant in the Ω-loop of TEM-1 β-lactamase changes the substrate profile via a large conformational change and an altered general base for catalysis. J. Biol. Chem., 2015, 290(16), 10382-10394.
[http://dx.doi.org/10.1074/jbc.M114.633438] [PMID: 25713062]
[25]
Levitt, P.S.; Papp-Wallace, K.M.; Taracila, M.A.; Hujer, A.M.; Winkler, M.L.; Smith, K.M.; Xu, Y.; Harris, M.E.; Bonomo, R.A. Exploring the role of a conserved class A residue in the Ω-Loop of KPC-2 β-lactamase: A mechanism for ceftazidime hydrolysis. J. Biol. Chem., 2012, 287(38), 31783-31793.
[http://dx.doi.org/10.1074/jbc.M112.348540] [PMID: 22843686]
[26]
Saves, I.; Burlet-Schiltz, O.; Maveyraud, L.; Samama, J-P.; Promé, J-C.; Masson, J-M. Mass spectral kinetic study of acylation and deacylation during the hydrolysis of penicillins and cefotaxime by beta-lactamase TEM-1 and the G238S mutant. Biochemistry, 1995, 34(37), 11660-11667.
[http://dx.doi.org/10.1021/bi00037a003] [PMID: 7547898]
[27]
Venkatachalam, K.V.; Huang, W.; LaRocco, M.; Palzkill, T. Characterization of TEM-1 beta-lactamase mutants from positions 238 to 241 with increased catalytic efficiency for ceftazidime. J. Biol. Chem., 1994, 269(38), 23444-23450.
[http://dx.doi.org/10.1016/S0021-9258(17)31536-3] [PMID: 8089110]
[28]
Jacob, F.; Joris, B.; Lepage, S.; Dusart, J.; Frère, J.M. Role of the conserved amino acids of the ‘SDN’ loop (Ser130, Asp131 and Asn132) in a class A β-lactamase studied by site-directed mutagenesis. Biochem. J., 1990, 271(2), 399-406.
[http://dx.doi.org/10.1042/bj2710399] [PMID: 2173561]
[29]
Kumar, G.; Biswal, S.; Nathan, S.; Ghosh, A.S. Glutamate residues at positions 162 and 164 influence the beta-lactamase activity of SHV-14 obtained from Klebsiella pneumoniae. FEMS Microbiol. Lett., 2018, 365(2), 365.
[http://dx.doi.org/10.1093/femsle/fnx259] [PMID: 29228168]
[30]
Hwang, J.; Cho, K-H.; Song, H.; Yi, H.; Kim, H.S. Deletion mutations conferring substrate spectrum extension in the class A β-lactamase. Antimicrob. Agents Chemother., 2014, 58(10), 6265-6269.
[http://dx.doi.org/10.1128/AAC.02648-14] [PMID: 25049254]
[31]
Baig, M.H.; Sudhakar, D.R.; Kalaiarasan, P.; Subbarao, N.; Wadhawa, G.; Lohani, M.; Khan, M.K.A.; Khan, A.U. Insight into the effect of inhibitor resistant S130G mutant on physico-chemical properties of SHV type beta-lactamase: A molecular dynamics study. PLoS One, 2014, 9(12), e112456.
[http://dx.doi.org/10.1371/journal.pone.0112456] [PMID: 25479359]
[32]
Lahiri, S.D.; Johnstone, M.R.; Ross, P.L.; McLaughlin, R.E.; Olivier, N.B.; Alm, R.A. Avibactam and class C β-lactamases: Mechanism of inhibition, conservation of the binding pocket, and implications for resistance. Antimicrob. Agents Chemother., 2014, 58(10), 5704-5713.
[http://dx.doi.org/10.1128/AAC.03057-14] [PMID: 25022578]
[33]
Khan, A.U.; Ali, A. Danishuddin; Srivastava, G.; Sharma, A. Potential inhibitors designed against NDM-1 type metallo-β-lactamases: An attempt to enhance efficacies of antibiotics against multi-drug-resistant bacteria. Sci. Rep., 2017, 7(1), 9207.
[http://dx.doi.org/10.1038/s41598-017-09588-1] [PMID: 28835636]
[34]
Somboro, A.M.; Osei Sekyere, J.; Amoako, D.G.; Essack, S.Y.; Bester, L.A. Diversity and proliferation of metallo-β-lactamases: A clarion call for clinically effective metallo-β-lactamase inhibitors. Appl. Environ. Microbiol., 2018, 84(18), 84.
[http://dx.doi.org/10.1128/AEM.00698-18] [PMID: 30006399]
[35]
Garau, G.; García-Sáez, I.; Bebrone, C.; Anne, C.; Mercuri, P.; Galleni, M.; Frère, J-M.; Dideberg, O. Update of the standard numbering scheme for class B β-lactamases. Antimicrob. Agents Chemother., 2004, 48(7), 2347-2349.
[http://dx.doi.org/10.1128/AAC.48.7.2347-2349.2004] [PMID: 15215079]
[36]
Hou, C.D.; Liu, J.W.; Collyer, C.; Mitić, N.; Pedroso, M.M.; Schenk, G.; Ollis, D.L. Insights into an evolutionary strategy leading to antibiotic resistance. Sci. Rep., 2017, 7, 40357.
[http://dx.doi.org/10.1038/srep40357] [PMID: 28074907]
[37]
Chen, J.; Chen, H.; Shi, Y.; Hu, F.; Lao, X.; Gao, X.; Zheng, H.; Yao, W. Probing the effect of the non-active-site mutation Y229W in New Delhi metallo-β-lactamase-1 by site-directed mutagenesis, kinetic studies, and molecular dynamics simulations. PLoS One, 2013, 8(12), e82080.
[http://dx.doi.org/10.1371/journal.pone.0082080] [PMID: 24339993]
[38]
Hawk, M.J.; Breece, R.M.; Hajdin, C.E.; Bender, K.M.; Hu, Z.; Costello, A.L.; Bennett, B.; Tierney, D.L.; Crowder, M.W. Differential binding of Co(II) and Zn(II) to metallo-β-lactamase Bla2 from Bacillus anthracis. J. Am. Chem. Soc., 2009, 131(30), 10753-10762.
[http://dx.doi.org/10.1021/ja900296u] [PMID: 19588962]
[39]
Wang, Z.; Fast, W.; Valentine, A.M.; Benkovic, S.J. Metallo-β-lactamase: Structure and mechanism. Curr. Opin. Chem. Biol., 1999, 3(5), 614-622.
[http://dx.doi.org/10.1016/S1367-5931(99)00017-4] [PMID: 10508665]
[40]
Garrity, J.D.; Bennett, B.; Crowder, M.W. Direct evidence that the reaction intermediate of metallo-β-lactamase L1 is metal bound. Biochemistry, 2005, 44(3), 1078-1087.
[http://dx.doi.org/10.1021/bi048385b] [PMID: 15654764]
[41]
Zhang, H.; Hao, Q. Crystal structure of NDM-1 reveals a common β-lactam hydrolysis mechanism. FASEB J., 2011, 25(8), 2574-2582.
[http://dx.doi.org/10.1096/fj.11-184036] [PMID: 21507902]
[42]
King, D.T.; Worrall, L.J.; Gruninger, R.; Strynadka, N.C.J. New Delhi metallo-β-lactamase: Structural insights into β-lactam recognition and inhibition. J. Am. Chem. Soc., 2012, 134(28), 11362-11365.
[http://dx.doi.org/10.1021/ja303579d] [PMID: 22713171]
[43]
Yuan, Q.; He, L.; Ke, H. A potential substrate binding conformation of β-lactams and insight into the broad spectrum of NDM-1 activity. Antimicrob. Agents Chemother., 2012, 56(10), 5157-5163.
[http://dx.doi.org/10.1128/AAC.05896-11] [PMID: 22825119]
[44]
Wommer, S.; Rival, S.; Heinz, U.; Galleni, M.; Frère, J-M.; Franceschini, N.; Amicosante, G.; Rasmussen, B.; Bauer, R.; Adolph, H-W. Substrate-activated zinc binding of metallo-β -lactamases: Physiological importance of mononuclear enzymes. J. Biol. Chem., 2002, 277(27), 24142-24147.
[http://dx.doi.org/10.1074/jbc.M202467200] [PMID: 11967267]
[45]
Fonseca, F.; Bromley, E.H.C.; Saavedra, M.J.; Correia, A.; Spencer, J. Crystal structure of Serratia fonticola Sfh-I: Activation of the nucleophile in mono-zinc metallo-β-lactamases. J. Mol. Biol., 2011, 411(5), 951-959.
[http://dx.doi.org/10.1016/j.jmb.2011.06.043] [PMID: 21762699]
[46]
Bebrone, C.; Delbrück, H.; Kupper, M.B.; Schlömer, P.; Willmann, C.; Frère, J-M.; Fischer, R.; Galleni, M.; Hoffmann, K.M.V. The structure of the dizinc subclass B2 metallo-β-lactamase CphA reveals that the second inhibitory zinc ion binds in the histidine site. Antimicrob. Agents Chemother., 2009, 53(10), 4464-4471.
[http://dx.doi.org/10.1128/AAC.00288-09] [PMID: 19651913]
[47]
Mojica, M.F.; Bonomo, R.A.; Fast, W. B1-metallo-β-lactamases: Where do we stand? CDT, 2016, 17(9), 1029-1050.
[http://dx.doi.org/10.2174/1389450116666151001105622] [PMID: 26424398]
[48]
Malabanan, M.M.; Amyes, T.L.; Richard, J.P. A role for flexible loops in enzyme catalysis. Curr. Opin. Struct. Biol., 2010, 20(6), 702-710.
[http://dx.doi.org/10.1016/j.sbi.2010.09.005] [PMID: 20951028]
[49]
Concha, N.O.; Janson, C.A.; Rowling, P.; Pearson, S.; Cheever, C.A.; Clarke, B.P.; Lewis, C.; Galleni, M.; Frère, J-M.; Payne, D.J.; Bateson, J.H.; Abdel-Meguid, S.S. Crystal structure of the IMP-1 metallo β-lactamase from Pseudomonas aeruginosa and its complex with a mercaptocarboxylate inhibitor: Binding determinants of a potent, broad-spectrum inhibitor. Biochemistry, 2000, 39(15), 4288-4298.
[http://dx.doi.org/10.1021/bi992569m] [PMID: 10757977]
[50]
Scrofani, S.D.B.; Chung, J.; Huntley, J.J.A.; Benkovic, S.J.; Wright, P.E.; Dyson, H.J. NMR characterization of the metallo-β-lactamase from Bacteroides fragilis and its interaction with a tight-binding inhibitor: Role of an active-site loop. Biochemistry, 1999, 38(44), 14507-14514.
[http://dx.doi.org/10.1021/bi990986t] [PMID: 10545172]
[51]
Chen, Y.; Minasov, G.; Roth, T.A.; Prati, F.; Shoichet, B.K. The deacylation mechanism of AmpC β-lactamase at ultrahigh resolution. J. Am. Chem. Soc., 2006, 128(9), 2970-2976.
[http://dx.doi.org/10.1021/ja056806m] [PMID: 16506777]
[52]
Kato-Toma, Y.; Iwashita, T.; Masuda, K.; Oyama, Y.; Ishiguro, M. pKa measurements from nuclear magnetic resonance of tyrosine-150 in class C beta-lactamase. Biochem. J., 2003, 371(Pt 1), 175-181.
[http://dx.doi.org/10.1042/bj20021447] [PMID: 12513696]
[53]
Tripathi, R.; Nair, N.N. Mechanism of acyl-enzyme complex formation from the Henry-Michaelis complex of class C β-lactamases with β-lactam antibiotics. J. Am. Chem. Soc., 2013, 135(39), 14679-14690.
[http://dx.doi.org/10.1021/ja405319n] [PMID: 24010547]
[54]
Jacoby, G.A. AmpC β-lactamases. Clin. Microbiol. Rev., 2009, 22(1), 161-182.
[http://dx.doi.org/10.1128/CMR.00036-08] [PMID: 19136439]
[55]
Crichlow, G.V.; Kuzin, A.P.; Nukaga, M.; Mayama, K.; Sawai, T.; Knox, J.R. Structure of the extended-spectrum class C β-lactamase of Enterobacter cloacae GC1, a natural mutant with a tandem tripeptide insertion. Biochemistry, 1999, 38(32), 10256-10261.
[http://dx.doi.org/10.1021/bi9908787] [PMID: 10441119]
[56]
Mallo, S.; Pérez-Llarena, F.J.; Kerff, F.; Soares, N.C.; Galleni, M.; Bou, G. A tripeptide deletion in the R2 loop of the class C beta-lactamase enzyme FOX-4 impairs cefoxitin hydrolysis and slightly increases susceptibility to beta-lactamase inhibitors. J. Antimicrob. Chemother., 2010, 65(6), 1187-1194.
[http://dx.doi.org/10.1093/jac/dkq115] [PMID: 20382725]
[57]
Kim, J.Y.; Jung, H.I.; An, Y.J.; Lee, J.H.; Kim, S.J.; Jeong, S.H.; Lee, K.J.; Suh, P-G.; Lee, H-S.; Lee, S.H.; Cha, S-S. Structural basis for the extended substrate spectrum of CMY-10, a plasmid-encoded class C beta-lactamase. Mol. Microbiol., 2006, 60(4), 907-916.
[http://dx.doi.org/10.1111/j.1365-2958.2006.05146.x] [PMID: 16677302]
[58]
Doi, Y.; Wachino, J.; Ishiguro, M.; Kurokawa, H.; Yamane, K.; Shibata, N.; Shibayama, K.; Yokoyama, K.; Kato, H.; Yagi, T.; Arakawa, Y. Inhibitor-sensitive AmpC β-lactamase variant produced by an Escherichia coli clinical isolate resistant to oxyiminocephalosporins and cephamycins. Antimicrob. Agents Chemother., 2004, 48(7), 2652-2658.
[http://dx.doi.org/10.1128/AAC.48.7.2652-2658.2004] [PMID: 15215122]
[59]
Maveyraud, L.; Golemi, D.; Kotra, L.P.; Tranier, S.; Vakulenko, S.; Mobashery, S.; Samama, J-P. Insights into class D β-lactamases are revealed by the crystal structure of the OXA10 enzyme from Pseudomonas aeruginosa. Structure, 2000, 8(12), 1289-1298.
[http://dx.doi.org/10.1016/S0969-2126(00)00534-7] [PMID: 11188693]
[60]
De Luca, F.; Benvenuti, M.; Carboni, F.; Pozzi, C.; Rossolini, G.M.; Mangani, S.; Docquier, J-D. Evolution to carbapenem-hydrolyzing activity in noncarbapenemase class D β-lactamase OXA-10 by rational protein design. Proc. Natl. Acad. Sci. USA, 2011, 108(45), 18424-18429.
[http://dx.doi.org/10.1073/pnas.1110530108] [PMID: 22042844]
[61]
Leonard, D.A.; Bonomo, R.A.; Powers, R.A. Class D β-lactamases: A reappraisal after five decades. Acc. Chem. Res., 2013, 46(11), 2407-2415.
[http://dx.doi.org/10.1021/ar300327a] [PMID: 23902256]
[62]
Santillana, E.; Beceiro, A.; Bou, G.; Romero, A. Crystal structure of the carbapenemase OXA-24 reveals insights into the mechanism of carbapenem hydrolysis. Proc. Natl. Acad. Sci. USA, 2007, 104(13), 5354-5359.
[http://dx.doi.org/10.1073/pnas.0607557104] [PMID: 17374723]
[63]
Launay, O.; Joly-Guillou, M.L.; Decré, D.; Crémieux, A.C. Beta-lactamase inhibitors. Presse Med., 1997, 26(10), 485-492.
[PMID: 9137377]
[64]
González-Bello, C.; Rodríguez, D.; Pernas, M.; Rodríguez, Á.; Colchón, E. β-lactamase inhibitors to restore the efficacy of antibiotics against superbugs. J. Med. Chem., 2020, 63(5), 1859-1881.
[http://dx.doi.org/10.1021/acs.jmedchem.9b01279] [PMID: 31663735]
[65]
Bush, K.; Bradford, P.A. β-lactams and β-lactamase inhibitors: An overview. Cold Spring Harb. Perspect. Med., 2016, 6(8), a025247.
[http://dx.doi.org/10.1101/cshperspect.a025247] [PMID: 27329032]
[66]
Carcione, D.; Siracusa, C.; Sulejmani, A.; Leoni, V.; Intra, J. Old and new beta-lactamase inhibitors: Molecular structure, mechanism of action, and clinical use. Antibiotics (Basel), 2021, 10(8), 995.
[http://dx.doi.org/10.3390/antibiotics10080995] [PMID: 34439045]
[67]
van den Akker, F.; Bonomo, R.A. Exploring additional dimensions of complexity in inhibitor design for serine β-lactamases: Mechanistic and intra- and inter-molecular chemistry approaches. Front. Microbiol., 2018, 9, 622.
[http://dx.doi.org/10.3389/fmicb.2018.00622] [PMID: 29675000]
[68]
Thomas, V.L.; Golemi-Kotra, D.; Kim, C.; Vakulenko, S.B.; Mobashery, S.; Shoichet, B.K. Structural consequences of the inhibitor-resistant Ser130Gly substitution in TEM β-lactamase. Biochemistry, 2005, 44(26), 9330-9338.
[http://dx.doi.org/10.1021/bi0502700] [PMID: 15981999]
[69]
Bush, K. Beta-lactamase inhibitors from laboratory to clinic. Clin. Microbiol. Rev., 1988, 1(1), 109-123.
[http://dx.doi.org/10.1128/CMR.1.1.109] [PMID: 3060240]
[70]
Buynak, J.D. Understanding the longevity of the β-lactam antibiotics and of antibiotic/β-lactamase inhibitor combinations. Biochem. Pharmacol., 2006, 71(7), 930-940.
[http://dx.doi.org/10.1016/j.bcp.2005.11.012] [PMID: 16359643]
[71]
Cantón, R.; Coque, T.M. The CTX-M β-lactamase pandemic. Curr. Opin. Microbiol., 2006, 9(5), 466-475.
[http://dx.doi.org/10.1016/j.mib.2006.08.011] [PMID: 16942899]
[72]
Philippon, A.; Labia, R.; Jacoby, G. Extended-spectrum beta-lactamases. Antimicrob. Agents Chemother., 1989, 33(8), 1131-1136.
[http://dx.doi.org/10.1128/AAC.33.8.1131] [PMID: 2679367]
[73]
Bonnefoy, A.; Dupuis-Hamelin, C.; Steier, V.; Delachaume, C.; Seys, C.; Stachyra, T.; Fairley, M.; Guitton, M.; Lampilas, M. In vitro activity of AVE1330A, an innovative broad-spectrum non-beta-lactam beta-lactamase inhibitor. J. Antimicrob. Chemother., 2004, 54(2), 410-417.
[http://dx.doi.org/10.1093/jac/dkh358] [PMID: 15254025]
[74]
Ehmann, D.E.; Jahić, H.; Ross, P.L.; Gu, R-F.; Hu, J.; Kern, G.; Walkup, G.K.; Fisher, S.L. Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor. Proc. Natl. Acad. Sci. USA, 2012, 109(29), 11663-11668.
[http://dx.doi.org/10.1073/pnas.1205073109] [PMID: 22753474]
[75]
Yang, Y.; Rasmussen, B.A.; Shlaes, D.M. Class A β-lactamases--enzyme-inhibitor interactions and resistance. Pharmacol. Ther., 1999, 83(2), 141-151.
[http://dx.doi.org/10.1016/S0163-7258(99)00027-3] [PMID: 10511459]
[76]
Yadav, T.C.; Agarwal, V.; Srivastava, A.K.; Raghuwanshi, N.; Varadwaj, P.; Prasad, R.; Pruthi, V. Insight into structure-function relationships of β-lactamase and BLIPs interface plasticity using protein-protein interactions. CPD, 2019, 25(31), 3378-3389.
[http://dx.doi.org/10.2174/1381612825666190911154650] [PMID: 31544712]
[77]
Wang, X.; Minasov, G.; Shoichet, B.K. The structural bases of antibiotic resistance in the clinically derived mutant β-lactamases TEM-30, TEM-32, and TEM-34. J. Biol. Chem., 2002, 277(35), 32149-32156.
[http://dx.doi.org/10.1074/jbc.M204212200] [PMID: 12058046]
[78]
Watkins, R.R.; Papp-Wallace, K.M.; Drawz, S.M.; Bonomo, R.A. Novel β-lactamase inhibitors: A therapeutic hope against the scourge of multidrug resistance. Front. Microbiol., 2013, 4, 392.
[http://dx.doi.org/10.3389/fmicb.2013.00392] [PMID: 24399995]
[79]
Doran, J.L.; Leskiw, B.K.; Aippersbach, S.; Jensen, S.E. Isolation and characterization of a beta-lactamase-inhibitory protein from Streptomyces clavuligerus and cloning and analysis of the corresponding gene. J. Bacteriol., 1990, 172(9), 4909-4918.
[http://dx.doi.org/10.1128/jb.172.9.4909-4918.1990] [PMID: 2203736]
[80]
Strynadka, N.C.J.; Jensen, S.E.; Johns, K.; Blanchard, H.; Page, M.; Matagne, A.; Frère, J-M.; James, M.N.G. Structural and kinetic characterization of a β-lactamase-inhibitor protein. Nature, 1994, 368(6472), 657-660.
[http://dx.doi.org/10.1038/368657a0] [PMID: 8145854]
[81]
Chow, D-C.; Rice, K.; Huang, W.; Atmar, R.L.; Palzkill, T. Engineering specificity from broad to narrow: Design of a β-Lactamase Inhibitory Protein (BLIP) variant that exclusively binds and detects KPC β-lactamase. ACS Infect. Dis., 2016, 2(12), 969-979.
[http://dx.doi.org/10.1021/acsinfecdis.6b00160] [PMID: 27756125]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy